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Abstract
Background: Hepatitis B virus (HBV) infection is an increasingly important cause of morbidity and mortality in HIV-infected
adults. This study aimed to determine the prevalence and incidence of HBV in the UK CHIC Study, a multicentre
observational cohort.
Methods and Findings: 12 HIV treatment centres were included. Of 37,331 patients, 27,450 had at least one test (HBsAg,
anti-HBs or anti-HBc) result post-1996 available. 16,043 were white, 8,130 black and 3,277 other ethnicity. Route of exposure
was homosexual sex 15,223 males, heterosexual sex 3,258 males and 5,384 females, injecting drug use 862 and other 2,723.
The main outcome measures used were the cumulative prevalence and the incidence of HBV coinfection. HBV susceptible
patients were followed up until HBsAg and/or anti-HBc seroconversion incident infection, evidence of vaccination or last
visit. Poisson regression was used to determine associated factors. 25,973 had at least one HBsAg test result. Participants
with HBsAg results were typically MSM (57%) and white (59%) (similar to the cohort as a whole). The cumulative prevalence
of detectable HBsAg was 6.9% (6.6 to 7.2%). Among the 3,379 initially HBV-susceptible patients, the incidence of HBV
infection was 1.7 (1.5 to 1.9)/100 person-years. Factors associated with incident infection were older age and IDU. The main
limitation of the study was that 30% of participants did not have any HBsAg results available. However baseline
characteristics of those with results did not differ from those of the whole cohort. Efforts are on-going to improve data
collection.
Conclusions: The prevalence of HBV in UK CHIC is in line with estimates from other studies and low by international
standards. Incident infection continued to occur even after entry to the cohort, emphasising the need to ensure early
vaccination.
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Introduction
Hepatitis B virus (HBV) is one of the world’s most important
infectious diseases, with one third of the world’s population having
been infected, approximately 350 million being chronically
infected and one million dying of the complications of HBV
infection each year [1]. An estimated 33.3 million people
worldwide are living with HIV infection and 1.8 million died in
2009 from AIDS-related causes [2]. Due to shared modes of
transmission (sexual, blood borne and mother-to-child) HBV and
HIV co-infection is common. Co-infection with HBV does not
appear to affect the rate of progression of HIV-disease (such as
progression to a new AIDS diagnosis) or virological or immuno-
logical responses to highly-active antiretroviral therapy (HAART),
although there are some conflicting data [3–6]. In contrast, HBV
outcomes are altered in the setting of HIV. In addition to the
higher incidence, there are lower rates of resolution of infection,
faster progression of liver disease in those who become chronic
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carriers, increased rates of adverse drug reactions [7] and
increased rates of liver-related death [8]. With the dramatically
improved survival of HIV positive individuals with access to
HAART [9] liver disease has become one of the most common
non-AIDS-related causes of mortality; in the prospective D:A:D
cohort liver disease was responsible for 14.5% of deaths, with
AIDS causing 31%, cardiovascular disease 11% and non-AIDS
cancers 9%. Viral hepatitis is the most important cause of these
deaths with 76% occurring in patients with hepatitis B and/or
hepatitis C co-infection [10].
Geographical differences exist in HBV incidence, prevalence
and genotype so that the quantitative impact of co-infection in the
UK cannot be extrapolated simply from international data.
Estimates of the prevalence of chronic HBV infection in the
general population in the UK are limited. Rates in low-risk HIV-
negative groups are low with 0.35% of antenatal samples positive
for HBsAg in 2008 [11]. An estimate of the prevalence in the HIV-
positive population was made by the EuroSIDA cohort in which
9.1% were co-infected with HBV in northern and central
European centres (which include the UK) [4]. Hepatitis B is a
preventable disease since an effective vaccine is available. Despite
the increased importance of HBV prevention in HIV-positive
patients and national policies that recommend vaccination [12],
coverage remains incomplete [13,14].
The UK Collaborative HIV Cohort (UK CHIC) Study
collects routine clinical data on patients aged over 16 years
attending any of 13 centres for HIV care. It records
demographics, clinical events, antiretroviral medication history
and laboratory test results, including results of hepatitis B and C
serology. The dataset, including data collected up to 2009,
contains the records of over 37,000 patients which is over one
third of all those diagnosed with HIV in the UK [15]. It thus
provides an exceptional resource for examining the epidemiol-
ogy and impact of HBV co-infection. In this analysis we have
used the UK CHIC dataset to estimate the prevalence and
incidence of HBV within the UK HIV positive population, and
to examine trends over time.
Methods
Data from the United Kingdom Collaborative HIV Cohort
(UK CHIC) Study was used for this analysis. This is an
observational cohort of HIV-positive individuals attending some
of the largest HIV treatment centres in the UK (see Appendix).
Data collected included information on demographics, single most
likely route of HIV exposure, antiretroviral history, laboratory test
results including HBV serology, AIDS defining events and deaths.
Of the 13 centres which provided data to UK CHIC, 12 included
HBV data and were included in this analysis. HBV data
comprised results of tests for hepatitis B surface antigen (HBsAg),
antibody to hepatitis B surface (anti-HBs), and antibody to
hepatitis B core (anti-HBc). Hepatitis B DNA results are not
available.
The number of individuals under follow up in each year from
1996 to 2009 was determined using first seen and last seen dates
and the cumulative proportion of these individuals with HBV data
available in each year (up to and including 2009) was calculated.
The HBV status for each individual was determined using their
last available HBsAg, anti-HBs and anti-HBc result by the end of
each year, with results carried forward if not performed, or
repeated, in that year. The test result combinations used to define
the HBV status of each individual are shown in Table 1; these
required a number of assumptions to be made when results were
missing or incomplete, and because HBV vaccination records were
not available in the dataset. Also, since HBV DNA data is not
available, some patients without HBsAg may have been misclas-
sified as uninfected when they in fact had HBsAg negative, DNA
positive hepatitis B.
The cumulative prevalence of HBV infection was calculated by
dividing the number of individuals with a positive HBsAg test
result by the number of individuals with an HBsAg test result at
any time up to the time period of interest.
Logistic regression was used to assess the association between
either having a HBsAg test result in the dataset, or having current
HBV infection, and demographic factors (age, ethnicity, risk
group), year of cohort entry, CD4 at cohort entry and HIV viral
load at cohort entry.
Table 1. Hepatitis B result combinations used to define hepatitis B status
HBsAg Anti-HBs Anti-HBc
Not exposed, susceptible Negative Negative Negative
Not exposed, possibly vaccinated Negative Missing Negative
Immune Vaccinated Negative Positive Negative
Resolved infection Negative Positive Positive
Either vaccinated or resolved infection Negative Positive Missing
Isolated anti-HBc Negative Negative Positive
Currently infected Positive Any Any
Unclassifiable (insufficient data) Negative Missing Missing or positive
Negative Negative Missing
Missing Any Any
HBsAg: Hepatitis B surface antigen. Anti-HBs: antibody to hepatitis B surface antigen. Anti-HBc: antibody to hepatitis B core antigen.
Note to Table 1: There are several potential explanations for results being recorded as missing, with varied consequences for the analysis. Tests may have been
undertaken but the data not available electronically and therefore not included in the exported dataset, or tests may not have been carried out in error or intentionally.
The latter is particularly likely where previous test results are known so that clinicians may have been able to infer the current HBV status, but the details of these are not
included in the dataset. In other situations, clinicians or the laboratory may have limited the tests requested, for example if HBsAg and anti-HBc were both detectable an
anti-HBs test might have been deemed unnecessary. Some missing results are less critical to the analysis than others, in that the result would not change the allocated
category. All those with missing HBsAg results have been put in the unclassifiable category.
doi:10.1371/journal.pone.0049314.t001
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Amongst individuals with a positive HBsAg test result indicating
current infection, subsequent HBsAg test results were reviewed in
order to further define their HBV status. Individuals were defined
as having chronic infection if they had a positive HBsAg test result
at least 6 months after their first positive HBsAg test result, with no
intervening negative result. Individuals without chronic HBV and
with at least one negative HBsAg test result after their first positive
HBsAg test result were defined as having had recent infection
which resolved. Individuals that did not meet the criteria for either
of these categories, for example those with no subsequent HBsAg
test results after a single positive HBsAg test result were defined as
infected, but not further classifiable.
Associations between the presence of recent HBV infection and
demographic and laboratory factors were assessed using logistic
regression.
In further analyses, the incidence of HBV infection was
calculated. Using all recorded test results within a year of the
first HBV test result, individuals were defined as having never
been infected with HBV if the result of anti-HBs was negative and
the results of HBsAg and anti-HBc were either negative or missing.
HBV infection, including both current and resolved infection, was
defined as a positive HBsAg result or a positive anti-HBc result. A
sensitivity analysis was performed limiting the definition to those
with initial negative results for all of HBsAg, anti-HBs and anti-
HBc. Incidence rates were calculated for patients who were shown
not to have already been infected. Time of infection was defined
by the first positive HBsAg or anti-HBc test result, and patients
were censored at their last visit or at their first positive anti-HBs
result (without a positive anti-HBc result, indicating vaccination
and therefore that the patient was deemed no longer susceptible).
Rates of HBV infection were determined by dividing the number
of newly infected individuals by the number of patient years of
follow up, and were stratified by demographic and laboratory
variables. Poisson regression was used to assess the associations
between incident HBV infection and other factors of interest. All
analyses were performed using SAS version 9.
The study obtained ethics approval from the West Midlands
Multi-centre Research Ethics Committee (number MREC/00/7/
47).
Results
Of the 37,331 individuals attending centres providing at least
some HBV test data, 27,450 (73.5%) had at least one HBV
serological test result and 25,973 (69.6%) had at least one HBsAg
test result available. Baseline characteristics of these individuals are
shown in Table 2. In line with the UK CHIC cohort as a whole,
individuals with HBV test results (either any HBV test result [data
not shown], or HBsAg specifically) were likely to be men who have
sex with men (MSM) and of white ethnicity. At the date of the first
test, the median CD4 count was 340 cells/mm3, the median HIV
viral load was 4.3 log copies/mL and the median age of
individuals was 35 years. The proportion of patients under follow
up with any HBV data recorded increased from 33% in 1997 to
88% in 2009.
Predictors of the Availability of HBsAg Test Results
In univariable analyses, patients of white ethnicity and of MSM
risk group were more likely to have a HBsAg test result than those
of black or other ethnicities and those of non-MSM risk groups
(p,0.0001). Individuals were also more likely to have a HBsAg test
result if they had higher CD4 counts (OR: 1.02 (95% CI: 1.02 to
1.03) per 50 cells higher) and higher viral loads at entry (1.08 (1.05
to 1.10) per 1 log higher). These variables remained significantly
associated with the likelihood of having a HBsAg test result in
multivariable analyses.
Cumulative Prevalence of HBsAg
Of the 25,973 patients with at least one HBsAg test result, 1,781
had at least one positive result, giving a cumulative HBsAg
prevalence of 6.9% (6.6% to 7.2%). Factors associated with a
positive result amongst all those with HBsAg test data are shown in
Table 3. In univariable analyses, those of black and other
ethnicities were more likely to have a positive HBsAg test result
compared to those of white ethnicity. Heterosexual females were
more likely to have a positive HBsAg test result compared to
MSM, who were more likely to be positive than heterosexual men.
Those who entered the cohort in earlier calendar years were also
more likely to have a positive HBsAg test result. No association
was seen with HIV viral load or age, although those with higher
CD4 counts at their first HBsAg test were less likely to have a
positive HBsAg test result. With the exception of the association
with gender, all associations with a positive HBsAg test result
remained statistically significant in multivariable analyses.
Resolution vs Chronicity
Of the 1,781 individuals who had ever had a positive HBsAg
test result, 758 patients could not be further classified as having
recent or chronic infection from the data available. Of the
remaining 1,023 individuals, 836 (81.7%) had chronic hepatitis B,
and 187 (18.3%) had recent infection which resolved. In
univariable analyses, patients with resolution of HBV were more
likely than those with chronic HBV infection to be of white
ethnicity (OR 0.45 (0.30 to 0.68) and 0.73 (0.43 to 1.26)
comparing black and other ethnicity to white ethnicity) and had
higher HIV viral loads at the time of their first positive HBsAg test
result (1.15 (1.01 to 1.32)). There were no differences between
exposure groups. After adjusting for potential confounders, only
ethnicity remained significantly associated with resolved HBV
Table 2. Baseline characteristics of those with and without
HBsAg test results.
All HBsAg test No HBsAg test
25973 11358
Ethnicity N (%) White 15348 (59.1) 5590 (49.2)
Black 7438 (28.6) 3447 (30.4)
Other 3187 (12.3) 2321 (20.4)
Exposure N (%) MSM 14743 (56.8) 3635 (32.0)
Heterosexual 7841 (30.2) 3491 (30.7)
IDU 773 (3.0) 616 (5.4)
Other 2616 (10.1) 3616 (31.8)
Year of entry N (%) 1996–1999 9323 (35.9) 4743 (41.8)
2000–2004 8290 (31.9) 2749 (24.2)
2005–2010 8360 (32.2) 3866 (34.0)
CD4 at first test (cells/mm3) Median (IQR) 340 (173 to
515)
300 (129 to 490)
VL at first test (log copies/ml) Median (IQR) 4.3 (3.1 to 5.0) 4.1 (2.9 to 4.9)
Age at first test (years) Median (IQR) 35 (30 to 41) 35 (30 to 41)
HBsAg: Hepatitis B surface antigen. MSM: men who have sex with men. IDU:
intravenous drug user. VL: HIV viral load. IQR: interquartile range.
doi:10.1371/journal.pone.0049314.t002
Hepatitis B in the UK Collaborative HIV Cohort
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e49314
infection (0.41 (0.25 to 0.67) and 0.66 (0.34 to 1.28) comparing
black and other ethnicity to white ethnicity).
Change in HBV Prevalence Over Time
Of the 2698 patients who had HBV test results recorded before
the end of 1996, the first year of the cohort, 185 (6.9%) had a
positive HBsAg result. In 2009, amongst the 22,734 patients under
follow up in that year, 19,953 had at least one HBV test recorded
and 1027 (5.1%)of these patients had a positive HBsAg test result.
Nine patients in 1996 and 25 in 2009 were positive for both
HBsAg and anti-HBS and although simultaneous positive HBsAg
and anti-HBs has been described [16] it is possible that these
results represented data errors. However excluding these did not
significantly change the prevalence estimations; 6.5% (176/2698)
in 1996 and 5.0% (1002/22,734) in 2009.
Considering the whole cohort (including those without hepatitis
B test results), current infection (defined as HBsAg positive) was
present in 3.0% of those seen for follow-up in 1996 and 4.5% of
those seen in 2009. The proportion of patients defined as immune
as a result of prior infection (resolved infection) increased from
2.5% in 1996 to 9.0% in 2009 and the proportion with isolated
anti-HBc increased from 1.5% to 2.8% over the same time period.
Combining these, gives an overall proportion of patients with
evidence of ever having been infected with HBV of 7.0% in 1996
increasing to 16.4% in 2009 (figure 1).
Incident HBV Infection
3379 patients could be categorised as susceptible to HBV
infection and subsequently contributed a total of 15,001 person-
years of follow up with serological test results available. Of these,
252 had a positive HBsAg or anti-HBc test result during the period
of observation, giving in an overall HBV incidence rate of 1.7 (1.5
to 1.9)/100 person-years. Table 4 shows the events, person years
of observation and associations with HBV incidence. HBV
exposure rates were highest in intravenous drug users (IDU), then
MSM, and lowest in heterosexuals. Individuals of older age and
those with prior AIDS diagnoses were more likely to acquire HBV,
but after adjusting for potential confounders, only risk group
remained significantly associated with incident infection. Further
test results were available for 200 patients after incident HBV and
of these 33 or 16.5% (11.6 to 22.4%) were HBsAg positive for at
least six months indicating that they had failed to resolve the
infection and had become chronically infected. A sensitivity
analysis, in which the definition of susceptible was restricted to
those with negative HBsAg, anti-HBs and anti-HBc results, found
45 events in 1,837 patients with 6,476 person-years of follow-up,
The incidence of HBV was thus 0.7 (0.5 to 0.9)/100 person-years.
Subsequent results were available for 36 of the 45 and 33.3% met
the definition of chronic infection.
‘Not infected’ groups
Individuals were defined as ‘not infected’ if they fell into one of
the following 3 groups: not exposed and susceptible; not exposed
but possibly vaccinated and immune; and vaccinated (Table 1).
Figure 1 shows trends over time for these groups, where the
denominator is all patients in the cohort (including those without
test data). Using the last known status of patients in each year, the
proportion of patients who were susceptible to HBV increased
from 1.9% in 1996 to 8.6% in 2009. The proportion of patients
who were not exposed but possibly vaccinated increased from
1.2% in 1996 to 14.8% in 2009 and the proportion of patients who
were immune due to vaccination increased from 1.4% in 1996 to
11.9% in 2009. The overall proportion of patients who were not
infected with HBV increased from 4.4% in 1996 to 35.2% in
2009.
Vaccination Status
Due to incomplete results, whether through lack of testing or
incomplete data capture, it is not possible to determine precisely
the number vaccinated and the number susceptible. Data on
vaccination history itself was not available as part of the UK
CHIC dataset. However if the analysis is limited to those with
sufficient test results available, it is possible to estimate the
coverage of vaccination among those who have not already been
Table 3. Associations between factors of interest and positive HBsAg status.
Univariable Multivariable
All OR (95% CI) P-value OR (95% CI) P-value
Ethnicity White 1 ,0.0001 1 ,0.0001
Black 1.38 (1.24 to 1.54) 2.53 (2.05 to 3.12)
Other 1. 25 (1.08 to 1.45) 1.73 (1.39 to 2.14)
Exposure MSM 1 ,0.0001 1 ,0.0001
Heterosexual (m) 0.75 (0.65 to 0.86) 0.43 (0.34 to 0.55)
Heterosexual (f) 1.44 (1.25 to 1.65) 0.87 (0.69 to 1.09)
IDU 1.22 (0.93 to 1.59) 1.45 (0.95 to 2.20)
Other 1.03 (0.88 to 1.22) 0.66 (0.51 to 0.86)
Year of entry 1996–1999 1.73 (1.53 to 1.95) ,0.0001 1.74 (1.44 to 2.11) ,0.0001
2000–2004 1.40 (1.23 to 1.60) 1.29 (1.10 to 1.50)
2005–2010 1 1
CD4 at CHIC entry (cells/mm3) Per 50 cells higher 0.94 (0.93 to 0.96) ,0.0001 0.94 (0.93 to 0.96) ,0.0001
VL at CHIC entry (log copies/ml) Per 1 log higher 1.01 (0.96 to 1.07) 0.59 0.93 (0.88 to 0.98) 0.01
Age at first test (years) Per 10 years older 1.00 (0.95 to 1.06) 0.90 1.01 (0.93 to 1.09) 0.88
OR: odds ratio. CI: confidence interval. MSM: men who have sex with men. IDU: intravenous drug user. VL: HIV viral load.
doi:10.1371/journal.pone.0049314.t003
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infected given by the number with the serological pattern of a
vaccine responder (detectable anti-HBs in the absence of anti-
HBc, and HBsAg) as a proportion of the sum of this group and
those classified as ‘‘never infected (susceptible)’’. This increased
from 42.0% in 1996 to 58.2% in 2009 (p,0.001, Chi squared).
Discussion
The cumulative prevalence of current HBV infection (HBsAg
positivity) in the UK CHIC cohort was 6.9% (6.6 to 7.2%). The
prevalence amongst those under follow-up and tested in 2009 was
5.1%. This is lower than the regional estimate of 9.1% from
EuroSIDA (northern and central Europe: UK, Eire, Norway,
Sweden, Denmark, Germany, Netherlands, Belgium, Luxem-
bourg, France and Switzerland). The prevalence of HBV infection
is related to patient characteristics including mode of HIV
transmission and place of birth (and hence the association with
ethnicity in this population). Of note we found that those of black
or other ethnicity and those with a history of IDU had a higher
prevalence while heterosexual men and women had lower
prevalence, when compared to MSM. Those who entered the
cohort earlier were more likely to have had a positive HBsAg test
result at some time during follow up. However this difference may
reflect longer follow up rather than a true decline in prevalence
over time. They were also less likely to have had HBV vaccination
or to have contracted HBV before HIV. The completeness of data
capture, which was lower earlier in the period of the UK CHIC
study could also have resulted in some bias; for example HBsAg
positive patients may have been more likely to have been retested
and so included in the dataset.
Using the last available HBsAg result for each individual, there
was a declining prevalence of current HBV infection from 6.9% in
1996 to 5.1% in 2009. This may be due to changes in
demographics, with fewer patients coming from, for example,
areas of high HBV prevalence in sub-Saharan Africa, or may
indicate better vaccination coverage and hence prevention of
infection. It may also be attributed to the marked increase in the
proportion of the cohort for which HBV status could be fully
defined, associated, with more complete data capture, with or
without more comprehensive testing in clinics. Of those with
current HBV infection for whom there was sufficient data, the
majority (81.7%) were HBsAg-positive for at least six months,
Figure 1. Hepatitis B status by calendar year. Proportion of patients with current or resolved HBV infection, never exposed to HBV and with
unclassifiable HBV status, stratified by calendar year.
doi:10.1371/journal.pone.0049314.g001
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meeting the definition of chronic hepatitis B. Some patients who
lost detectable HBsAg within 6 months could have been late
chronic infections, but the rate of HBsAg loss in those with chronic
infection is very low so that misclassifications will be rare [17].
HIV infection is associated with a lower rate of clearance after
acute HBV infection, with one fifth likely to proceed to chronic
hepatitis [18,19]. Since the majority of HIV infections in black
patients in the UK were acquired in Africa [20] it is likely that
most HBV infections in non-white individuals in this cohort will
have been acquired prior to HIV infection, either by vertical or
early childhood infection, which predominates in endemic areas.
Most white patients were either MSM or IDU, and therefore likely
to have only been at risk of HBV infection as adults. The higher
proportion of resolved infections amongst the white ethnic group is
therefore consistent with the lower risk of chronicity in adults, even
in those who are HIV positive, compared to that seen in vertical or
early childhood acquired infection.
The proportion of those never infected with HBV who were
protected by vaccine increased between 1996 and 2009 (from
42.0% to 58.2%). This may be related both to an improvement in
vaccine coverage and to improved vaccine response rates as the
mean CD4 count of the cohort has increased. Nonetheless, around
40% of those not already infected remained at risk of HBV
infection at the time of the last available test result. In the absence
of vaccination data we cannot be certain how much of this is due
to failure to vaccinate, and how much to the impaired immune
response to vaccine in HIV positive individuals. National
guidelines continue to recommend vaccination for all HIV-positive
patients at diagnosis, with a repeat course in non-responders.
Repeating the course when CD4 counts have increased on
treatment may also be worthwhile. Regular review or clinical
audit, as recommended by the British HIV Association, should
enable providers to monitor their service performance and adjust
clinic practice accordingly [12].
Whether due to failure to vaccinate, or inadequate response, we
found evidence of incident HBV infection occurring in the cohort
at a rate of 1.7 cases per 100 person-years of follow up, though this
figure must be interpreted with caution in view of the lower value
of 0.7 cases per 100 person-years found in the sensitivity analysis.
Infection frequently gave rise to chronic hepatitis B, in 16.5% of
cases, which is consistent with published data [18,19]. The risk of
incident HBV infection was higher for IDU than for MSM and
higher for MSM than for heterosexuals, perhaps reflecting poorer
vaccination coverage in the former group and lower ongoing risk
in the latter. Of note older patients had a higher risk of new HBV
infection, demonstrating the continuing risk of sexually transmitted
infection in this group, possibly combined with failure of vaccine
protection over time.
Overall the proportion of patients in UK CHIC with any HBV
results available was just under 75% with about 70% having at
Table 4. Associations between demographic, laboratory and clinical characteristics and incidence of hepatitis B.
Univariable Multivariable
All Events/person-years RR (95% CI) P-value RR (95% CI) P-value
Ethnicity White 185/10553 1 0.37 –
Black 50/3093 0.92 (0.67 to 1.26)
Other 17/1355 0.72 (0.44 to 1.18)
Risk group MSM 183/9191 1 ,0.0001 1 ,0.0001
Heterosexual (m) 19/1542 0.62 (0.39 to 0.99) 0.59 (0.36 to 0.94)
Heterosexual (f) 20/2321 0.43 (0.27 to 0.69) 0.44 (0.28 to 0.70)
IDU 14/409 1.72 (1.00 to 2.96) 1.70 (0.98 to 2.92)
Other 16/1541 0.52 (0.31 to 0.87) 0.53 (0.32 to 0.89)
Current VL ,50 99/5800 1 0.98 –
(copies/ml) .50 126/7558 1.02 (0.79 to 1.33)
Missing 27/1643 0.99 (0.65 to 1.49)
Age at first test ,35 70/5327 1 0.03 1 0.06
(years) 35–45 122/6396 1.45 (1.08 to 1.95) 1.40 (1.04 to 1.89)
.45 60/3278 1.39 (0.99 to 1.97) 1.37 (0.96 to 1.95)
Previous AIDS No 190/12114 1 0.04 1 0.10
Yes 62/2888 1.37 (1.03 to 1.82) 1.28 (0.96 to 1.72)
Current CD4 ,200 35/1919 1.19 (0.79 to 1.78) 0.58 –
(cells/mm3) 201–350 57/3496 1.06 (0.75 to 1.51)
351–500 70/3614 1.26 (0.91 to 1.76)
.500 71/4628 1
Missing 19/1345 0.92 (0.55 to 1.53)
Current calendar year 1996–1999 34/2015 1.20 (0.81 to 1.79) 0.17 –
2000–2002 56/3002 1.33 (0.95 to 1.87)
2003–2005 79/4063 1.39 (1.02 to 1.89)
.2005 83/5921 1
RR: relative risk. CI: confidence interval. MSM: men who have sex with men. IDU: intravenous drug user. VL: HIV viral load.
doi:10.1371/journal.pone.0049314.t004
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least one result for HBsAg. UK national guidelines recommend
that all patients should have HBV tests at HIV diagnosis, and have
their status re-checked annually [12]. Data is submitted to UK
CHIC electronically from routine clinic systems and databases. As
clinical information systems in use in treatment centres have
developed, particularly with integration with laboratory systems,
completeness of data has increased over time. Efforts are ongoing
to audit and improve data extraction and collection. The
EuroSIDA study also uses electronic databases but is supplement-
ed by manually collected data from paper records, which could
result in less missing data. Despite this, at the time of estimating
HBV prevalence, EuroSIDA contained HBsAg results on only
5728 patients (58.4% of all patients in the study) from a total of 29
countries [4]. Published data from EuroSIDA also included only a
single HBsAg result from each patient without other HBV
serology and has been reported only at the regional level (with
the UK included in the northern and central Europe region). Thus
we believe the current study provides a more detailed picture of
HBV co-infection in the UK than has been possible before,
estimating not only HBV prevalence but also incidence and the
proportion still at risk of infection.
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